-

Bayer Donates $500K to Support Maui Community After Devastating Fires

  • Cash and Essential Healthcare Products Donation Aims to Aid Relief Efforts

WHIPPANY, N.J.--(BUSINESS WIRE)--In the aftermath of the devastating fires that have affected the Maui community, Bayer stands in solidarity with those impacted and offers heartfelt condolences for the losses endured. With roots spanning more than 50 years in Maui County, Bayer is firmly committed to providing immediate relief and sustained support for recovery and rebuilding.

Guided by its vision, 'Health for All, Hunger for None,' Bayer will contribute $500,000 to relief efforts on the island – a cash donation of $250,000 alongside a donation of essential healthcare products valued at $250,000.

This donation underscores Bayer’s dedication to addressing crucial needs of the community and the company’s Crop Science employees at our farms on Maui during this unimaginable time. It focuses on the key areas of supporting relief efforts, increasing access to food for those displaced and continuing to assess the needs of the community on an ongoing basis and contribute to local organizations as additional needs emerge.

Of the cash donation, $150,000 will be directed to the Hawaii Community Foundation's Maui Strong program, which plays a vital role in coordinating resources for recovery efforts. An additional $50,000 will be contributed to the Maui Food Bank, supporting their mission to provide relief and distribute food through community partners to assist those in need. Recognizing the evolving nature of the situation, Bayer will also provide $50,000 in future contributions to local organizations to help support the ongoing efforts as needs emerge.

To supplement donations made to local organizations, Bayer will donate vital healthcare supplies valued at $250,000 to Direct Relief, an organization working closely with 19 Hawaii healthcare partners to deliver immediate medical aid to those in need on the ground. The donation includes 4,000 essential items specifically requested by Direct Relief such as Bayer Aspirin, Aleve, Claritin, and an antibiotic, addressing critical healthcare requirements.

In addition to these contributions, Bayer's employees on Maui, Molokai, and Oahu have demonstrated remarkable compassion by donating more than 3,000 pounds of essential supplies, including food, water, toiletries, towels, baby items, sleeping bags, household necessities, and clothing. Many Bayer employees have also dedicated their time to contributing to the relief efforts by volunteering to serving meals and sorting donations, showcasing a genuine commitment to assisting their fellow community members.

Furthermore, colleagues across Bayer have united to show their support for Maui. Through the Bayer Fund matching program, employees have generously made monetary donations, with Bayer Fund matching these contributions. This collective effort underscores Bayer's commitment to standing alongside the Maui community during these trying times.

"We are grateful to be a part of the Maui community and are fully committed to providing support during this unprecedented time," stated Alan Takemoto, Government Affairs Lead, Bayer Hawaii. "Our pledge is to help offer not only immediate relief but also to contribute to the sustained recovery and revitalization of Maui."

As the journey toward recovery continues, Bayer remains dedicated to standing by the Maui community for years to come.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

About Bayer Fund

Bayer Fund, a philanthropic arm of Bayer in the U.S., is a nonprofit organization dedicated to strengthening the communities where Bayer customers and employees live and work by providing funding for food and nutrition, education, and health and wellness projects. For more Information visit https://www.fund.bayer.us.

Contacts

Brian Leake
Director, External Communications
Brian.Leake@Bayer.com
(314) 370.3285

Monica Ivey
Corporate Relations Lead
Bayer Hawaii
Monica.Ivey@Bayer.com
(808) 221.1166

Bayer


Release Versions

Contacts

Brian Leake
Director, External Communications
Brian.Leake@Bayer.com
(314) 370.3285

Monica Ivey
Corporate Relations Lead
Bayer Hawaii
Monica.Ivey@Bayer.com
(808) 221.1166

More News From Bayer

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches. Current...

U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer...

Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in Vienna, Austria, June 4-7, 2025. KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic...
Back to Newsroom